Alan N Engelman

US Patent:

20030013196, Jan 16, 2003

Filed:

Nov 21, 2001

Appl. No.:

09/990879

Inventors:

Alan Engelman - Brookline MA, US
Wolfgang Hofmann - Bonn, DE
Joseph Sodroski - Medford MA, US
Richard Lu - Jamaica Plain MA, US

Assignee:

Dana-Farber Cancer Institute, Inc.

International Classification:

C12N015/86
C12N007/00

US Classification:

435/456000, 435/235100, 435/320100

Abstract:

The invention is directed to a lentiviral vector system that can be used for episomal replication of a desired gene. The vector system contains a first vector containing a lentiviral gag gene encoding a lentiviral gag protein, a second vector containing an env gene encoding a functional envelope protein, and a lentiviral pol gene encoding a lentiviral pol protein. The pol protein is at least integrase, but that the integrase has been modified so that it is not capable of integration. This pol gene can be on the first or second vectors or on a third vector. The lentiviral gag and pol and the envelope protein are not on a single vector, and these vectors do not contain nucleotides to effectively package lentiviral RNA. The system also contains another vector having a nucleic acid sequence encoding a target molecule operably linked to a component of an episomal replicon and a lentiviral packaging sequence.

US Patent:

20070031822, Feb 8, 2007

Filed:

Jan 22, 2004

Appl. No.:

10/542517

Inventors:

Eric Devroe - Cambridge MA, US
Alan Engelman - Brookline MA, US
Pamela Silver - Cambridge MA, US

International Classification:

C12Q 1/70
C12Q 1/68
C12Q 1/48

US Classification:

435005000, 435006000, 435015000

Abstract:

Methods of identifying agents that modulate NDR kinases, including those that modulate NDR1 and NDR2 kinases and methods of using those agents to inhibit retroviral pathogenesis are among the methods described herein.

US Patent:

20110142854, Jun 16, 2011

Filed:

May 18, 2009

Appl. No.:

12/992797

Inventors:

Nan Yan - Boston MA, US
Alan Engelman - Brookline MA, US
Judy Lieberman - Brookline MA, US

Assignee:

IMMUNE DISEASE INSTITUTE, INC. - Boston MA
DANA-FARBER CANCER INSTITUTE, INC. - Boston MA

International Classification:

A61K 39/42
C12Q 1/68
C12N 5/02
A61K 38/00
A61K 31/7088
A61P 31/18

US Classification:

4241591, 435 612, 435375, 514 38, 514 44 A

Abstract:

Described herein are methods and compositions for the inhibition of retroviral integration and replication. The methods and compositions inhibit the activity of one or more components of the SET complex or base excision repair enzymes and induce autointegration of retroviral double-stranded nucleic acid.